Vnitr Lek 2018, 64(6):654-658 | DOI: 10.36290/vnl.2018.089

The IBD outpatient care in the clinical practice

Luděk Hrdlička
Gastroenterologické oddělení Polikliniky Budějovická, Medicon a.s., Praha

The number of patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis) has increased steadily. Gastroenterology outpatient secondary type centres play very important role in the care for these patients. Their clinical practice was assessed in our study. The data was obtained using a structured questionnaire concerned on 4 major topics (the centre characteristics, diagnosis, therapy and patient's monitoring). Obtained data was compared with both local and international recommendations and showed high professional standards of care.

Keywords: Crohn's disease; diagnosis; inflammatory bowel disease; outpatient care; patient's monitoring; therapy; ulcerative colitis

Received: October 22, 2017; Accepted: April 18, 2018; Published: June 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hrdlička L. The IBD outpatient care in the clinical practice. Vnitr Lek. 2018;64(6):654-658. doi: 10.36290/vnl.2018.089.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Lukáš M. Možnosti medikamentózní léčby Crohnovy choroby a ulcerózní kolitidy. Interní Med 2011; 13(11): 422-426.
    2. Hrdlička L. Péče o IBD pacienty: klinická praxe v gastroenterologických ambulancích sekundárního typu v ČR. Gastroent Hepatol 2014; 68(5): 456-460. Go to original source...
    3. Modigliani R, Mary JY, Simon JF et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990; 98(4): 811-818. Go to original source... Go to PubMed...
    4. Landi B, Anh TN, Cortot A et al. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992; 102(5): 1647-1653. Go to original source... Go to PubMed...
    5. Carbonnel F, Lavergne A, Lemann M et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 1994; 39(7): 1550-1557. Go to original source... Go to PubMed...
    6. Horsthuis K, Bipat S, Bennink RJ et al. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: metaanalysis of prospective studies. Radiology 2008; 247(1): 64-79. Dostupné z DOI: <http://dx.doi.org/10.1148/radiol.2471070611>. Go to original source... Go to PubMed...
    7. Parisinos CA, Mclntyre VE, Heron T et al. Magnetic resonance follow-through imaging for evaluation of disease activity in ileal Crohn's disease: an observational, retrospective cohort study. Inflamm Bowel Dis 2010; 16(7): 1219-1226. Dostupné z DOI: <http://dx.doi.org/10.1002/ibd.21168>. Go to original source... Go to PubMed...
    8. Horjus C et al. Magnetic resonance enterography in the assessment of the disease activity in Crohn's disease. A retrospective study ECCO Congress, Prague 2010; P047.
    9. Girlich C, Ott C, Strauch U et al. Clinical feature and bowel ultrasound in Crohn's disease - does additional information from magnetic resonance imaging affect therapeutic approach and when does extended diagnostic investigation make sense? Digestion 2011; 83(1-2): 18-23. Dostupné z DOI: <http://dx.doi.org/10.1159/000314590>. Go to original source... Go to PubMed...
    10. Marino M, Berretti D, Toso F et al. Usefullness of ultrasound in small bowel Crohn's disease: comparison with magnetic resonance for extension, complications and disease activity. Gut 2011; 60(Suppl 1): A210.2. Dostupné z DOI: <http://dx.doi.org/10.1136/gut.2011.239301.443>. Go to original source...
    11. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006; 55(3): 426-431. Dostupné z DOI: <http://dx.doi.org/10.1136/gut.2005.069476>. Go to original source... Go to PubMed...
    12. Keshet R, Boursi B, Maoz R et al. Diagnostic and prognostic significance of serum C-reactive protein levels in patients admitted to the department of medicine. Am J Med Sci 2009; 337(4): 248-255. Dostupné z DOI: <http://dx.doi.org/10.1097/MAJ.0b013e31818af6de>. Go to original source... Go to PubMed...
    13. Vieira A, Fang CB, Rolim EG et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Res Notes 2009; 2: 221. Dostupné z DOI: <http://dx.doi.org/10.1186/1756-0500-2-221>. Go to original source... Go to PubMed...
    14. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004; 39(10): 1017-1020. Dostupné z DOI: <http://dx.doi.org/10.1080/00365520410007971>. Go to original source... Go to PubMed...
    15. Dignass A, Lindsay JO, Sturm A et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6(10): 991-1030. Dostupné z DOI: <http://dx.doi.org/10.1016/j.crohns.2012.09.002>. Go to original source... Go to PubMed...
    16. Regueiro M, Kip KE, Schraut W et al. Crohn's disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflamm Bowel Dis 2011; 17(1): 118-126. Dostupné z DOI: <http://dx.doi.org/10.1002/ibd.21355>. Go to original source... Go to PubMed...
    17. Dignass A, Van Assche G, Lindsay JO et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohn's Colitis 2010; 4(1): 28-62. Dostupné z DOI: <http://dx.doi.org/10.1016/j.crohns.2009.12.002>. Erratum in J Crohns Colitis 2010; 4(3): 353. Go to original source... Go to PubMed...
    18. Prokopová L, Ďuricová D, Bortlík M et al. Doporučené postupy pro podávání aminosalicylátů u nemocných s idiopatickými střevními záněty. Gastroent Hepatol 2012; 66(5): 391-400.
    19. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease. Cochrane Database Syst Rev 2005; (1): CD003715. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD003715.pub2>. Go to original source... Go to PubMed...
    20. Ford AC, Kane SV, Khan KJ et al. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106(4): 617-629. Dostupné z DOI: <http://dx.doi.org/10.1038/ajg.2011.71>. Go to original source... Go to PubMed...
    21. Ford AC, Khan KJ, Talley NJ et al. 5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis. Am J Gastroenterol 2011; 106(3): 413-420. Dostupné z DOI: <http://dx.doi.org/10.1038/ajg.2010.317>. Go to original source... Go to PubMed...
    22. Gordon M, Naidoo K, Thomas AG et al. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst Rev 2011; (1): CD008414. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD008414.pub2>. Go to original source... Go to PubMed...
    23. Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev 2010; (12): CD008870. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD008870>. Go to original source... Go to PubMed...
    24. Steinhart AH, Forbes A, Mills EC et al. Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2007; 25(12): 1389-1399. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365-2036.2007.03324.x>. Go to original source... Go to PubMed...
    25. Ďuricová D. Mesalazin u Crohnovy nemoci: obsoletní nebo neprávem opomíjená léčba? Gastroent Hepatol 2013; 67(1): 22-24.
    26. Ananthakrishnan AN, McGinley EL, Binion DG. Does it matter where you are hospitalized for inflammatory bowel disease? A nationwide analysis of hospital volume. Am J Gastroenterol 2008; 103(11): 2789-2798. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1572-0241.2008.02054.x>. Go to original source...
    27. Nguyen GC, Steinhart AH. Nationwide patterns of hospitalizations to centers with high volume of admissions for inflammatory bowel disease and their impact on mortality. Inflamm Bowel Dis 2008; 14(12): 1688-1694. Dostupné z DOI: <http://dx.doi.org/10.1002/ibd.20526>. Go to original source... Go to PubMed...
    28. Burns EM, Bottle A, Aylin P et al. Volume analysis of outcome following restorative proctocolectomy. Br J Surg 2011; 98(3): 408-417. Dostupné z DOI: <http://dx.doi.org/10.1002/bjs.7312>. Go to original source... Go to PubMed...
    29. Kennedy ED, Rothwell DM, Cohen Z et al. Increased experience and surgical technique lead to improved outcome after ileal pouch-anal anastomosis: a population-based study. Dis Colon Rectum 2006; 49(7): 958-965. Dostupné z DOI: <http://dx.doi.org/10.1007/s10350-006-0521-6>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.